Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-08-19
2010-12-07
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S183000, C435S337000, C435S338000, C435S344000, C530S350000, C530S387100, C530S387700, C530S388250, C530S388260, C436S064000
Reexamination Certificate
active
07846673
ABSTRACT:
Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer. Preferred are new antibodies, specific for non-immunodominant epitopes of MN/CA IX, are useful to detect soluble CA IX (s-CA IX) in body fluids, preferably in combination with antibodies specific to immunodominant epitopes of MN/CA IX.
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5955075 (1999-09-01), Zavada et al.
patent: 5972353 (1999-10-01), Zavada et al.
patent: 5981711 (1999-11-01), Zavada et al.
patent: 5989838 (1999-11-01), Zavada et al.
patent: 6004535 (1999-12-01), Zavada et al.
patent: 6027887 (2000-02-01), Zavada et al.
patent: 6051226 (2000-04-01), Zavada et al.
patent: 6069242 (2000-05-01), Zavada et al.
patent: 6093548 (2000-07-01), Zavada et al.
patent: 6204370 (2001-03-01), Zavada et al.
patent: 6297041 (2001-10-01), Zavada et al.
patent: 6297051 (2001-10-01), Zavada et al.
patent: 6770438 (2004-08-01), Zavada et al.
patent: 6774117 (2004-08-01), Zavada et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 00/24913 (2000-05-01), None
patent: WO 2004/017923 (2004-03-01), None
patent: WO 2008/103327 (2008-08-01), None
Barathova et al. (Br. J. Cancer. Jan. 15, 2008; 98 (1):129-136).
Banks et al. (Eur. J. Biochem. 1976; 71: 469-473).
Zavadora et al. (Oncol. Rep. May 2005; 13 (5): 977-982).
Holotnakova et al. (Pflugers Arch. May 2008; 456 (2): 323-337).
Vordermark et al. (Int. J. Radiat. Oncol. Biol. Phys. Mar. 15, 2005; 61 (4): 1197-1207).
Zavada et al. (Br. J. Cancer. Sep. 15, 2003; 89 (6): 1067-1071).
Roessler et al. (Mol. Cell. Prot. 2006; 5 (11): 2092-2101).
Roessler et al. (Clin. Can. Res. 2005; 11 (18): 6550-6557).
Zolg et al. (Mol. Cell. Prot. 2004; 3 (4): 345-354).
Rae et al. (International Journal of Cancer 2000; 88: 726-732).
Ward (Developmental Oncology 1985; 21: 91-106).
Critchfield (Disease Markers 1999; 15: 108-111).
Sidransky (Science 1997; 278: 1054-1058).
Tockman et al. (Cancer Research 1992; 52: 2711s-2718s).
Leibovich et al. (J. Clin. Oncol. Oct. 20, 2007; 25 (3): 4757-4764).
Chia et al. (J. Clin. Oncol. Aug. 15, 2001; 19 (16): 3660-3668).
Watson et al. (Br. J. Cancer. 2003; 88: 1065-1070).
Brewer et al. (Gynecol. Oncol. Dec. 1996; 63 (3): 337-344).
Eriksen et al. (Radiother. Oncol. 2007; 83: 383-388).
De Schutter et al. (BMC Cancer. Apr. 25, 2005; 5: 42; published on the Internet; pp. 1-11).
Sekine et al. (J. Clin. Oncol. Oct. 1985; 3 (10): 1355-1363).
Diotti et al (Int. J. Biol. Markers. Sep.-Dec. 1987; 2 (3): 161-168).
Griffiths et al. (Acta Derm. Venereol. Jan. 1996; 76 (1): 12-5).
Saga et al (Acta Obstet. Gynecol. Scand. 1990; 69 (2): 175-181).
Zavada et al. (Br. J. Cancer. Sep. 2003; 89 (15): 1067-71).
Hyrsl et al. (Neoplasma. 2009; 56 (4): 298-302).
Li et al. (Biochem. Biophys. Res. Commun. Aug. 28, 2009; 386 (3): 488-92).
Zhou et al. (Urology. Feb. 2010; 75 (2): 257-61).
Airley et al., “Glucose Transporter Glut-1 Expression Correlates with Tumor Hypoxia and Predicts Metastasis-free Survival in Advanced Carcinoma on the Cervix,”Clinical Cancer Research, 7: 928-934 (Apr. 2001).
Bander et al., “Renal cancer imaging with monoclonal antibody G250,”J. Urol., 155 (5 Suppl.): 583A (Abstract 1088).
Chia et al., “Prognostic significance of a novel hypoxia- regulated marker, carbonic anhydrase IX, in invasive breast carcinoma,”J. Clin. Oncol., 19(16): 3660-3668 (Aug. 15, 2001).
Giatromanolaki et al., “Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer,”Cancer Research, 61(21): 7992-7998 (Nov. 1, 2001).
Griffiths et al., “The macrophate—a novel system to deliver gene therapy to pathological hypoxia,”Gene Therapy, 7: 255-262 (2000).
Horton, J., “Trastuzumab Use in Breast Cancer: Clinical Issues,”Cancer Control, 9(6): 499-507 (2002).
Ivanov et al., “Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer,”American Journal of Pathology, 158(3): 905-919 (Mar. 2001).
Kaluz et al., “Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hypoxia-inducible Factor 1 Stabilization: A Role for Phosphatidylinositol 3′-Kinase,”Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
Kivela et al., “Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours,”Histochemistry and Cell Biology, 114(3): 197-204 (2000).
Kuter, I., “Breast Cancer,”The Oncologist, 6: 338-346 (2001).
Lieskovska et al., “Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma,”Neoplasma, 46(1): 17-24 (1999).
Loncaster et al., “Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix,”Caner Res, 61(17): 6394-6399 (Sep. 1, 2001).
Oosterwijk and Debruyne, “Radiolabeled monoclonal antibody G250 in renal-cell carcinoma,”World Journal of Urology, 13: 186-190 (1995).
Opavsky et al., “Human MN/CA9 Gene a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships,”Genomics, 33: 480-487 (1996).
Parkkila et al., “Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro,”PNAS(USA), 97(5): 2220-2224 (Feb. 29, 2000).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova et al., “A Novel Quasi-viral Agent, MaTu, Is a Two-Component System,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts,”Gastroenterology, 112: 398-408 (1997).
Revillion et al., “ERBB2Oncogene in Human Breast Cancer and its Clinical Significance,”Euro J. Cancer, 34: 791-808 (1998).
Steffens et al., “Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250,”Journal of Clinical Oncology, 15(4): 1529-1537 (Apr. 1997).
Steffens et al., “Radioimmunotherapy with 131I-cG250 Monoclonal antibody in Patients with Metastasized RCC, Phase I/II Study,”Journal of Urology, 159 (5 Suppl.): Abstract No. 562 (May 1998).
Teicher et al., “A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies,”Anticancer Research, 13: 1549-1556 (1993).
Trikha et al., “Monoclonal antibodies as therapeutics in oncology,”Current Opinion in Biotechnoogy, 13(6): 609-614 (2002).
Turner et al., “MN Antigen Expression in Normal, Preneoplastic, and Neoplastic Esophagus: a Clinicopathogical Study of a New Cancer-Associated Biomarker,”Hum. Pathol., 28(6): 740-744 (Jun. 1997).
Uemura et al., “MN/CA IX/G250 as a p
Gut Marta Ortova
Pastorek Jaromir
Pastorekova Silvia
Zatovicova Miriam
Zavada Jan
Harland Joan C.
Institute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Rawlings Stephen L
Shimei Barbara A.
LandOfFree
Soluble form of carbonic anhydrase IX (s-CA IX), assays to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble form of carbonic anhydrase IX (s-CA IX), assays to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble form of carbonic anhydrase IX (s-CA IX), assays to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160213